

Eurofins Clinical Diagnostics UK Launch pTau181 Blood Test to Rule Out Alzheimer's Associated Amyloid Pathology

Working in collaboration with Torbay and South Devon NHS Foundation Trust and Roche Diagnostics to verify the assay, Eurofins Clinical Diagnostics UK have released the pTau181 test to rule out the Alzheimer's associated amyloid pathology.

With dementia affecting almost 1 million people in the UK, Alzheimer's disease accounts for 60-80% of cases*, access to this new test will streamline the clinical approach to Alzheimer's disease diagnosis and patient care.

pTau181 is targeted for use during the assessment of patients with cognitive decline before the onset of Alzheimer's disease symptoms.

pTau181 is a minimally invasive blood test with a high negative predictive value of ~94% to rule out Alzheimer's amyloid pathology, making it a valuable test for healthcare professionals. Positive results should form part of wider analysis and diagnosis of Alzheimer's disease in conjunction with other clinical information and further investigative testing such as CSF and PET scans.

Available from Eurofins Clinical Diagnostics in the UK, pTau181 is aimed at patients aged 55 to 80 years old with subjective cognitive decline, non-specific cognitive impairment, or suspected mild cognitive impairment (MCI) and for patients undergoing evaluation for Alzheimer's disease where amyloid pathology needs to be ruled out early.

With a rapid turnaround time, patients can be directed to the most appropriate clinical pathway faster, aiding diagnosis and helping improve quality of life.

For further information please contact Eurofins Clinical Diagnostics UK:
enquiries@ctuk.eurofins.com

Over
1 million
people in
the UK
have
dementia

Alzheimer's
accounts for
60-80%
of cases

pTau181
is a simple
rule out
blood test